Abstract
Adenine arabinoside (ARA-A) and its monophosphate (ARA-AMP) are potent inhibitors of hepatitis B virus, but they have not been shown to beneficially alter the natural history of chronic type B hepatitis. Analysis of responders to ARA-AMP therapy has shown that responses can be temporary and that truly long-term beneficial responses are rare. Most long-term responses occur in patients with marked elevations in serum aminotransferase activities and severe chronic active hepatitis. This group of patients, however, may also be the most likely to have a spontaneous improvement in chronic hepatitis. Analyses from England suggest that male homosexual patients have a lower response rate to ARA-AMP than heterosexual patients. This difference has not been shown in studies from the United States. The effect of HTLV-III infection on the course and outcome of hepatitis B virus infection and on clinical responses to antiviral therapy needs further evaluation. In view of the side-effects of ARA-AMP and its marginal efficacy, it is unlikely to play a role as a single agent in the therapy of this important chronic liver disease. However, the use of ARA-AMP after a short course of immunosuppressive therapy is an approach to therapy that deserves future investigation in prospective controlled trials.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.